Mary Beckerle - Johnson Johnson Independent Director

<div class='circular--portrait' style='background:#4E8BFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>JJ</div>
JNJ -- USA Stock  

 Earnings Call  This Week

  Director
Dr. Mary C. Beckerle, Ph.D., is an Independent Director of the Company. She has served as CEO of Huntsman Cancer Institute at the University of Utah since 2006. She is the associate vice president for cancer affairs and a distinguished professor of biology and oncological sciences at the University of Utah. Dr. Beckerle joined the faculty of the University of Utah in 1986 and currently holds the Jon M. Huntsman Presidential Endowed Chair. Dr. Beckerle has served on the National Institute of Health Advisory Committee to the Director, on the Board of Directors of the American Association for Cancer Research, as president of the American Society for Cell Biology, and as the Chair of the American Cancer Society Council for Extramural Grants. She currently serves on a number of scientific advisory boards, including the Medical Advisory Board of the Howard Hughes Medical Institute, and the Scientific Advisory Boards of the National Center for Biological Sciences at the Tata Institute of Fundamental Research in India, the Mechanobiology Institute in Singapore, and the Dana FarberHarvard Cancer Center. Dr. Beckerle held a Guggenheim Fellowship at the Curie Institute in Paris, received the Utah Governors Medal for Science and Technology in 2001, the Sword of Hope Award from the American Cancer Society in 2004 and is an elected Fellow of the American Academy of Arts and Sciences and the American Philosophical Society. Dr. Beckerle was also named a National Association of Corporationrationrate Directors Governance Fellow in 2012.
Age: 64  Director Since 2015      
732 214-0332  www.jnj.com

Johnson Johnson Management Efficiency

Johnson Johnson has Return on Asset of 8.83 % which means that on every $100 spent on asset it made $8.83 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 28.55 %, implying that it generated $28.55 on every 100 dollars invested. Johnson Johnson management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Johnson Johnson Return on Investment is decreasing as compared to previous years. The last year's value of Return on Investment was reported at 19.14. The current Return on Average Assets is estimated to increase to 0.009237, while Return on Invested Capital is estimated to decrease to 0.29. Johnson Johnson Net Current Assets as percentage of Total Assets are decreasing as compared to previous years. The last year's value of Net Current Assets as percentage of Total Assets was reported at 7.98. The current Return on Average Assets is estimated to increase to 0.009237, while Tax Assets are estimated to decrease to under 6.8 B. Johnson Johnson Current Liabilities is increasing as compared to previous years. The last year's value of Current Liabilities was reported at 30.54 Billion. The current Tax Liabilities is estimated to increase to about 20.2 B, while Total Liabilities is estimated to decrease to under 90.3 B.
The company has 27.58 B in debt with debt to equity (D/E) ratio of 0.45, which is OK given its current industry classification. Johnson Johnson has a current ratio of 1.28, demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Hans WijersGlaxoSmithKline PLC
2013
Philip HamptonGlaxoSmithKline PLC
2015
Etienne DavignonGilead Sciences
N/A
Karen WalkerEli Lilly And
2018
Nicholas MooreGilead Sciences
2004
Steven MayerGrifols S A
2016
Carlos RepresasMerck Company
2009
Karen HornEli Lilly And
2012
Michel DemareAstrazeneca PLC
2019
Baroness VaderaAstrazeneca PLC
2011
John NoseworthyMerck Company
2017
Shriti VaderaAstrazeneca PLC
2011
Craig ThompsonMerck Company
2008
Peter WendellMerck Company
2003
Urs RohnerGlaxoSmithKline PLC
2015
Kevin LoftonGilead Sciences
2009
Pierre LandoltNovartis AG
1996
Stephen WrightGW Pharmaceuticals Plc
2005
Richard WhitleyGilead Sciences
2008
Inigo MardonesGrifols S A
2017
Jose GrasGrifols S A
2000

Company Summary

Johnson Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 132200 people.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 132,200 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent Director
Jennifer Doudna, Independent Director
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee
William Perez, Independent Director
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer
Marillyn Hewson, Independent Director
Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer
Mary Coleman, Independent Director
Michael Ullmann, VP, General Counsel and Member of Executive Committee
Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals
Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer
Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals
Mary Beckerle, Independent Director
Sandra Peterson, Group Worldwide Chairman and Member of Executive Committee
Scott Davis, Director
Louise Mehrotra, Vice President Investor Relations
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices
Ronald Williams, Independent Director
Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer
D Davis, Independent Director
Hubert Joly, Independent Director
Anne Mulcahy, Lead Independent Director
Joseph Wolk, Chief Financial Officer, Executive Vice President
Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer
Ian Davis, Independent Director
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee
Mark McClellan, Independent Director
Charles Prince, Independent Director
Eugene Washington, Independent Director
Dominic Caruso, CFO, VP of Fin. and Member of Executive Committee
Peter Fasolo, Chief Human Resource Officer, Executive Vice President
Susan Lindquist, Independent Director
Mark Weinberger, Independent Director

Stock Performance Indicators

Did you try this?

Run Insider Screener Now

   

Insider Screener

Find insiders across different sectors to evaluate their impact on performance
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page